MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

aTyr Pharma Company Profile (NASDAQ:LIFE)

Consensus Ratings for aTyr Pharma (NASDAQ:LIFE) (?)
Ratings Breakdown: 3 Hold Rating(s), 1 Buy Rating(s)
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: $44.00 (1,482.73% upside)

Analysts' Ratings History for aTyr Pharma (NASDAQ:LIFE)
Show:
DateFirmActionRatingPrice TargetActions
5/12/2016BMO Capital MarketsReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/31/2016William BlairDowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/14/2016JPMorgan Chase & Co.Reiterated RatingOverweightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/16/2015Citigroup Inc.Initiated CoverageNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for aTyr Pharma (NASDAQ:LIFE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/11/2016Q1($0.70)($0.68)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/30/2016Q4($0.52)($0.70)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q3($0.48)($0.48)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($0.53)($0.74)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
6/18/2015Q115($0.41)($9.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313$0.97$1.02$926.10 million$936.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q2 2013$0.96$0.72$952.06 million$944.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013$1.04$1.07$958.56 million$963.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2013Q4 2012$1.11$1.11$988.85 million$998.90 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312$0.89$0.92$907.91 million$911.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2012$0.97$0.96ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/7/2012$1.04$1.06ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/25/2011$0.88$0.94ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011$0.95$0.89ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/26/2011$0.85$0.85ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/3/2011$0.87$0.90ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for aTyr Pharma (NASDAQ:LIFE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.70)($0.70)($0.70)
Q2 20161($0.68)($0.68)($0.68)
Q3 20161($0.69)($0.69)($0.69)
Q4 20161($0.70)($0.70)($0.70)
(Data provided by Zacks Investment Research)
Dividend History for aTyr Pharma (NASDAQ:LIFE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for aTyr Pharma (NASDAQ:LIFE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/11/2016Grove MatsuokaInsiderBuy12,412$3.04$37,732.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2016Paul SchimmelDirectorBuy66,219$4.18$276,795.42View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2016Paul SchimmelDirectorBuy9,835$3.85$37,864.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/12/2016Paul SchimmelDirectorBuy9,127$3.71$33,861.17View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/11/2016Paul SchimmelDirectorBuy32,659$3.57$116,592.63View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2016Paul SchimmelDirectorBuy85,000$3.22$273,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2016Paul SchimmelDirectorBuy40,000$3.19$127,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/6/2016Paul SchimmelDirectorBuy25,000$3.20$80,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016John MendleinCEOBuy2,500$3.55$8,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/5/2016Paul SchimmelDirectorBuy25,000$3.52$88,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015James E FlynnInsiderBuy50,000$14.00$700,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015Sofinnova Venture Partners Ix,Major ShareholderBuy320,000$14.00$4,480,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013David C UprichardDirectorSell2,010$74.04$148,820.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/28/2013John A CottinghamInsiderSell60,000$74.03$4,441,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for aTyr Pharma (NASDAQ:LIFE)
DateHeadline
06/29/16 04:49 PMWhat Next for aTyr Pharma Inc Stock After Today's Huge Decline? - Press Telegraph
06/29/16 04:49 PMShares Up in Session: aTyr Pharma Inc. (NASDAQ:LIFE) - Telanagana Press
06/29/16 04:49 PMWatching Stock Volatility for: aTyr Pharma Inc. (NASDAQ:LIFE) - Engelwood Daily
06/28/16 09:49 AMAtyr Pharma Incorporated (NASDAQ:LIFE) Short Interest Decreased By 6.41% - Press Telegraph
06/17/16 07:43 AMGlobal Tuberculosis Pipeline 2016 Market Report on 64 Companies - PR Newswire (press release)
06/16/16 04:17 PMATYR PHARMA INC Files SEC form 8-K, Change in Directors or Principal Officers -
06/10/16 04:01 PMaTyr Pharma, Inc. :LIFE-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016 -
06/08/16 05:16 PMATYR PHARMA INC. (NASDAQ:LIFE) Financial Condition Compared to S&P 500 - CML News
06/03/16 05:21 PMAtyr Pharma Incorporated (NASDAQ:LIFE) Shorted Shares Increased By 7.31% - HNN
06/03/16 05:21 PMaTyr Pharma Inc (NASDAQ:LIFE) Stock Update & Estimates - Stock Tick Tock
06/03/16 07:43 AMaTyr Pharma to Present at Jefferies 2016 Healthcare Conference - Stockhouse - aTyr Pharma to Present at Jefferies 2016 Healthcare ConferenceStockhouseSAN DIEGO, June 3, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's ...and more »
06/02/16 05:15 PMaTyr Pharma Inc (NASDAQ:LIFE) Quarterly EPS Estimate At $-0.74 - Investor Newswire - aTyr Pharma Inc (NASDAQ:LIFE) Quarterly EPS Estimate At $-0.74Investor NewswireFirst Call stated that aTyr Pharma Inc (NASDAQ:LIFE) can touch $9.00 in coming one year. For the next quarter, the per-share earnings target is $-0.74 and for ongoing fiscal at $-2.79. EPS target for next year is $-2.80 versus the mean EPS of $-2.56 ...and more »
05/26/16 03:01 PMATYR PHARMA INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/23/16 11:52 AMFast Moving Stocks: aTyr Pharma (NASDAQ:LIFE), Public Service Enterprise Group (NYSE:PEG), ShoreTel, (NASDAQ ... - KC Register - Fast Moving Stocks: aTyr Pharma (NASDAQ:LIFE), Public Service Enterprise Group (NYSE:PEG), ShoreTel, (NASDAQ ...KC RegisterOn 11 May, aTyr Pharma Inc. (NASDAQ:LIFE) reported that, General and administrative expenses were $4.1 million and $2.3 million for the quarters ended March 31, 2016 and 2015, respectively. The increase of $1.8 million was due primarily to a $1.6 ...
05/23/16 11:52 AMaTyr Pharma Inc (NASDAQ:LIFE) One-Year Price Target At $9.00 - Stocks Daily - aTyr Pharma Inc (NASDAQ:LIFE) One-Year Price Target At $9.00Stocks DailyFirst Call has set a 52-week price target of $9.00 on aTyr Pharma Inc (NASDAQ:LIFE) stock after completion of its survey. For the approaching quarter, EPS estimate is set at $-0.74 and for underway fiscal at $-2.79. This estimate for next year is $-2 ...and more »
05/17/16 11:35 PMaTyr Pharma Inc (NASDAQ:LIFE) Comprehensive Income At $-0.171 - Stocks Daily - aTyr Pharma Inc (NASDAQ:LIFE) Comprehensive Income At $-0.171Stocks DailyFor the year ended 2015-12-31, aTyr Pharma Inc (NASDAQ:LIFE)comprehensive income was $-0.171 millions whereas for the quarter ended 2015-12-31, it was $-0.171 millions. aTyr Pharma Inc (NASDAQ:LIFE) posted $-47.973 millions on combined net ...aTyr Pharma Inc (NASDAQ:LIFE) Hovering Around $3.06Enterprise Leaderall 2 news articles »
05/16/16 12:00 PMaTyr Pharma Inc (NASDAQ:LIFE) One-Year Price Projection At $8 - Investor Newswire - aTyr Pharma Inc (NASDAQ:LIFE) One-Year Price Projection At $8Investor NewswireSell-side analysts are certain on the prospect of aTyr Pharma Inc (NASDAQ:LIFE) stock. As of 2016-05-15, the stock ABR stands at 2.33. This type of rating states that whenever a stock has a score of 5, investors should avoid investing in such stocks ...and more »
05/13/16 12:13 AMaTyr Pharma, Inc. (NASDAQ:LIFE) Is Trading Down – Insider Trading Activity - aTyr Pharma, Inc. has been the object of insider buying activity recently. Yesterday See Remarks Grove Matsuoka disclosed the purchase of 12,412 shares. The shares sold for $3.06. Matsuoka now owns $37,981 of the stock per the Form 4 SEC filing. John ...
05/11/16 04:07 PMaTyr Pharma Announces First Quarter 2016 Operating Results - [at noodls] - SAN DIEGO, May 11, 2016/PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, ...
05/11/16 03:22 PMAtyr Pharma reports 1Q loss -
05/11/16 03:08 PMATYR PHARMA INC Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financia -
05/10/16 07:01 PMaTyr Pharma Inc (NASDAQ:LIFE) Comprehensive Income At $-0.171 For Period Ended 2015-12-31 - Stocks Daily - aTyr Pharma Inc (NASDAQ:LIFE) Comprehensive Income At $-0.171 For Period Ended 2015-12-31Stocks DailyFor the year ended 2015-12-31, aTyr Pharma Inc (NASDAQ:LIFE)comprehensive income was $-0.171 millions while for the quarter ended 2015-12-31, it was $-0.171 millions. aTyr Pharma Inc (NASDAQ:LIFE) posted $-47.973 millions on consolidated net ...aTyr Pharma Inc (NASDAQ:LIFE) Is $-25.12 Off Its 52-Week HighEnterprise Leaderall 2 news articles »
05/10/16 07:01 PMHC Sector Updates: Dynavax Technologies Corporation (DVAX), IDEXX Laboratories Inc. (IDXX), aTyr Pharma Inc (LIFE) - share market updates (press release) - share market updates (press release)HC Sector Updates: Dynavax Technologies Corporation (DVAX), IDEXX Laboratories Inc. (IDXX), aTyr Pharma Inc (LIFE)share market updates (press release)Shares of Dynavax Technologies Corporation (NASDAQ:DVAX) ended Monday session in green amid volatile trading. The shares closed up +0.98 points or 6.96% at $15.07 with 889,176.00 shares getting traded. Post opening the session at $14.15, the ...and more »
05/09/16 11:59 PMaTyr Pharma Inc (NASDAQ:LIFE) One-Year Mean Price Target At $8 - Investor Newswire - aTyr Pharma Inc (NASDAQ:LIFE) One-Year Mean Price Target At $8Investor NewswireSell-side analysts are confident on the future outlook of aTyr Pharma Inc (NASDAQ:LIFE) stock. As of 2016-05-08, the stock has an ABR of 2.33 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the basis of estimates of ...and more »
05/06/16 07:00 PMHC Stocks Alerts: aTyr Pharma Inc (LIFE), Cytori Therapeutics Inc (CYTX), CytRx Corporation (CYTR) - share market updates (press release) - HC Stocks Alerts: aTyr Pharma Inc (LIFE), Cytori Therapeutics Inc (CYTX), CytRx Corporation (CYTR)share market updates (press release)Shares of aTyr Pharma Inc (NASDAQ:LIFE) ended Thursday session in red amid volatile trading. The shares closed down -0.12 points or -3.59% at $3.22 with 233,366.00 shares getting traded. Post opening the session at $3.37, the shares hit an intraday low ...and more »
05/05/16 06:41 AMaTyr Pharma Appoints Grove Matsuoka as Senior Vice President, Product Programs and Planning - [at noodls] - SAN DIEGO, May 5, 2016/PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, ...
05/03/16 06:56 PMToday's Stocks: Pandora Media (NYSE:P), aTyr Pharma (NASDAQ:LIFE), Ampco-Pittsburgh Corp. (NYSE:AP), Fusion ... - KC Register - Today's Stocks: Pandora Media (NYSE:P), aTyr Pharma (NASDAQ:LIFE), Ampco-Pittsburgh Corp. (NYSE:AP), Fusion ...KC RegisterOn 29 April, aTyr Pharma Inc. (NASDAQ:LIFE) provides an overview of the aTyr Pharma, Inc. 's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for aTyr Pharma, Inc., complete with comparative analysis ...
05/03/16 06:56 PMaTyr Pharma Inc (NASDAQ:LIFE) Comprehensive Income At $-0.068 Millions For Quarter Closed 2015-09-30 - Stocks Daily - aTyr Pharma Inc (NASDAQ:LIFE) Comprehensive Income At $-0.068 Millions For Quarter Closed 2015-09-30Stocks DailyFor the year ended 2015-09-30, aTyr Pharma Inc (NASDAQ:LIFE) comprehensive income was $-0.068 millions whereas for the quarter ended 2015-09-30, the comprehensive income was $-0.068 millions. aTyr Pharma Inc (NASDAQ:LIFE) posted $-47.973 ...aTyr Pharma Inc (NASDAQ:LIFE) 50-day MA At $4.2866Enterprise Leaderall 2 news articles »
05/02/16 07:48 PMaTyr Pharma Inc (NASDAQ:LIFE) ABR Of 2.33 - Investor Newswire - aTyr Pharma Inc (NASDAQ:LIFE) ABR Of 2.33Investor NewswireThere are numerous brokerages operating in the market, and each one of them uses a different process to prepare the research reports on a stock. As a result, investors have to study more than one research report before taking an investment call on a stock.and more »
04/29/16 09:50 AMaTyr Pharma to Present at Upcoming May Investor Conferences - [at noodls] - SAN DIEGO, April 29, 2016/PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, ...
04/27/16 07:12 PMAtyr Pharma Incorporated (NASDAQ:LIFE) Sellers Increased By 9.4% Their Shorts - The Post - Atyr Pharma Incorporated (NASDAQ:LIFE) Sellers Increased By 9.4% Their ShortsThe PostThe stock of Atyr Pharma Incorporated (NASDAQ:LIFE) registered an increase of 9.4% in short interest. LIFE's total short interest was 912,300 shares in April as published by FINRA. Its up 9.4% from 833,900 shares, reported previously. With 213,600 ...and more »
04/26/16 07:03 PMInvestor News: aTyr Pharma Inc (NASDAQ:LIFE) under Investigation concerning potential Securities Laws Violations - GroundReport - Investor News: aTyr Pharma Inc (NASDAQ:LIFE) under Investigation concerning potential Securities Laws ViolationsGroundReportAn investigation for investors in NASDAQ:LIFE shares over potential securities laws violations by aTyr Pharma in connection certain financial statements was announced. Investors who purchased shares of aTyr Pharma Inc (NASDAQ:LIFE), have certain ...aTyr Pharma Inc (NASDAQ:LIFE) EBITDA Yearly Stands At $-44.25 MillionsStocks DailyaTyr Pharma Inc (NASDAQ:LIFE) 200-day MA At $7.20Enterprise Leaderall 3 news articles »
04/20/16 07:18 PMInvestigation for Investors in Shares of aTyr Pharma Inc (NASDAQ:LIFE) over Possible Violations of Securities Laws Announced - San Diego, CA -- (SBWIRE) -- 04/19/2016 -- An investigation was announced for investors of aTyr Pharma Inc (NASDAQ:LIFE) shares over potential securities laws violations by aTyr Pharma and certain of its directors and officers was announced. Investors who ...
04/19/16 08:06 PMStocks in focus: aTyr Pharma Inc (LIFE), Ironwood Pharmaceuticals (IRWD) - News Oracle - Stocks in focus: aTyr Pharma Inc (LIFE), Ironwood Pharmaceuticals (IRWD)News OracleaTyr Pharma Inc (NASDAQ:LIFE) declined -0.71% friday and closed at $4.19. The company's market capitalization is at $98.50 Million with an average trading volume of 626,535.00 shares. The total number of Outstanding Shares Held by the company are ...and more »
04/18/16 08:07 PMStock's Price Moves: Wright Medical Group NV (NASDAQ:WMGI) , aTyr Pharma, Inc. (NASDAQ:LIFE) - Street Updates - Stock's Price Moves: Wright Medical Group NV (NASDAQ:WMGI) , aTyr Pharma, Inc. (NASDAQ:LIFE)Street UpdatesaTyr Pharma, Inc. (NASDAQ:LIFE) after beginning at $4.25, closed at $4.19 by cutting down -0.71% in recent trading session. Most recent session's volume of 824.14 thousand shares greater than its average volume of 372.16 thousand shares. The company ...
04/15/16 07:21 PMPaul Schimmel invests in 66219 by purchasing aTyr Pharma (LIFE) Stock shares - Washington News Wire - Washington News WirePaul Schimmel invests in 66219 by purchasing aTyr Pharma (LIFE) Stock sharesWashington News WireaTyr Pharma logo aTyr Pharma (NASDAQ:LIFE) Director Paul Schimmel bought 66,219 shares of the stock in a transaction dated Thursday, April 14th. The stock was purchased at an average price of $4.18 per share, with a total value of $276,795.42.Paul Schimmel Buys 66219 Shares of aTyr Pharma (LIFE) StockWeb Breaking Newsall 2 news articles »
04/15/16 01:51 AMAtyr Pharma Inc (LIFE) Files Form 4 Insider Buying : Paul Schimmel Buys 9835 Shares - Market Digest - Atyr Pharma Inc (LIFE) Files Form 4 Insider Buying : Paul Schimmel Buys 9835 SharesMarket DigestAtyr Pharma Inc (LIFE): Paul Schimmel , director of Atyr Pharma Inc purchased 9,835 shares on Apr 13, 2016. The Insider buying transaction was reported by the company on Apr 14, 2016 to the Securities and Exchange Commission. The shares were ...
04/14/16 08:43 PMHealthcare Sector Companies for Investors: aTyr Pharma Inc (LIFE), Ligand Pharmaceuticals Inc. (LGND) - News Oracle - Healthcare Sector Companies for Investors: aTyr Pharma Inc (LIFE), Ligand Pharmaceuticals Inc. (LGND)News OracleaTyr Pharma Inc (NASDAQ:LIFE) surged 3.10% yesterday and closed at $3.99. The company's market capitalization is at $101.00 Million with an average trading volume of 524,017.00 shares. The total number of Outstanding Shares Held by the company are ...
04/14/16 08:43 PMStocks within Investors Screening: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) , aTyr Pharma, Inc. (NASDAQ:LIFE) - Street Updates - Stocks within Investors Screening: Jazz Pharmaceuticals plc (NASDAQ:JAZZ) , aTyr Pharma, Inc. (NASDAQ:LIFE)Street UpdatesIn the past trading session, aTyr Pharma, Inc. (NASDAQ:LIFE) highlighted upward shift of +3.10% or +0.12 points to $3.99. The company traded a volume of 969.92 thousand shares over average volume of 339.7 thousand shares. Trailing twelve month period, ...and more »
04/13/16 07:09 PMHealthcare Gainers: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), aTyr Pharma Inc. (NASDAQ:LIFE), Cara ... - KC Register - Healthcare Gainers: Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), aTyr Pharma Inc. (NASDAQ:LIFE), Cara ...KC RegisterAdamis Pharmaceuticals Corporation (NASDAQ:ADMP) announced that it has successfully completed its previously announced acquisition (the “Acquisition”) of US Compounding, Inc. Upon the closing of this transaction, USC has become a wholly-owned ...and more »
04/13/16 07:09 PMPaul Schimmel invests in 9127 by purchasing aTyr Pharma (LIFE) Stock shares - Washington News Wire - Washington News WirePaul Schimmel invests in 9127 by purchasing aTyr Pharma (LIFE) Stock sharesWashington News WireaTyr Pharma logo aTyr Pharma (NASDAQ:LIFE) Director Paul Schimmel bought 9,127 shares of aTyr Pharma stock in a transaction that occurred on Tuesday, April 12th. The stock was bought at an average price of $3.71 per share, with a total value of ...Paul Schimmel Acquires 85000 Shares of aTyr Pharma (LIFE) StockThe Vista VoiceaTyr Pharma (LIFE) Jumps: Stock Adds 13.1% in SessionZacks.comHere's A Reason aTyr Pharma (LIFE) Stock is Rising TodayTheStreet.comMas Market News -Web Breaking News -Zergwatchall 36 news articles »
04/12/16 07:52 PMNASDAQ Bulls: Amyris, Inc. (NASDAQ:AMRS), aTyr Pharma Inc. (NASDAQ:LIFE), Net 1 Ueps Technologies Inc ... - KC Register - NASDAQ Bulls: Amyris, Inc. (NASDAQ:AMRS), aTyr Pharma Inc. (NASDAQ:LIFE), Net 1 Ueps Technologies Inc ...KC RegisterShareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by aTyr Pharma Inc. (NASDAQ:LIFE) and certain of its officers. aTyr Pharma is a biotherapeutics company that engages in the discovery ...and more »
04/12/16 07:15 AMaTyr Pharma (LIFE) Jumps: Stock Adds 13.1% in Session -
04/11/16 07:08 PMLower close ahead of earnings - Shares of Cliffs Natural Resources (NYSE: CLF) climbed again. Bargain hunters lifted shares of aTyr Pharma (Nasdaq: LIFE). Rising crude oil prices lifted shares of Mid-con Energy Partners (Nasdaq: MCEP). On the downside Zacks Equity Research named Genocea ...
04/11/16 11:13 AMMonday 4/11 Insider Buying Report: LIFE, UBA - So let's look at two noteworthy recent insider buys. At aTyr Pharma ( LIFE), a filing with the SEC revealed that on Wednesday, Director Paul Schimmel bought 25,000 shares of LIFE, at a cost of $3.20 each, for a total investment of $80,000. Schimmel was up ...
04/09/16 06:36 PMBiotech Stocks in the Spotlight: Viking Therapeutics Inc (NASDAQ:VKTX), aTyr Pharma Inc. (NASDAQ:LIFE), Intercept ... - The Point Review - The Point ReviewBiotech Stocks in the Spotlight: Viking Therapeutics Inc (NASDAQ:VKTX), aTyr Pharma Inc. (NASDAQ:LIFE), Intercept ...The Point ReviewaTyr Pharma Inc. (NASDAQ:LIFE)'s stock on April 8, 2016 traded at beginning with a price of $3.25 and when day-trade ended the stock showed no change to end at $3.20. aTyr Pharma Inc. (NASDAQ:LIFE)'s showed weekly performance of -16.01%.and more »
04/07/16 08:58 PMaTyr Pharma (LIFE) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of aTyr ... - PR Newswire (press release) - The Vista VoiceaTyr Pharma (LIFE) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of aTyr ...PR Newswire (press release)SAN DIEGO, April 7, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by aTyr Pharma, Inc. (NASDAQ: LIFE) and certain of its officers. aTyr Pharma is a ...aTyr Pharma (LIFE) Director Paul Schimmel Buys 25000 SharesThe Vista VoiceAtyr Pharma Inc (LIFE) Files Form 4 Insider Buying : Paul Schimmel Buys 25000 SharesEverything HUDSONFY2016 EPS Estimates for aTyr Pharma Lowered by William Blair (LIFE)Financial Market NewsRiversideGazette.com -Benchmark Monitorall 13 news articles »
04/07/16 12:17 PMaTyr Pharma (LIFE) Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of aTyr Pharma, Inc.; Encourages Investors to Contact the Firm for Additional Information - [PR Newswire] - SAN DIEGO, April 7, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by aTyr Pharma, Inc. (NASDAQ: LIFE) and certain ...
04/07/16 01:06 AMAtyr Pharma Inc (LIFE) Files Form 4 Insider Buying : Paul Schimmel Buys 25000 Shares - SCSUCollegian - Atyr Pharma Inc (LIFE) Files Form 4 Insider Buying : Paul Schimmel Buys 25000 SharesSCSUCollegianAtyr Pharma Inc Executive reported Insider buying to the SEC on Apr 6, 2016 in a Form 4 Filing. Paul Schimmel , director of Atyr Pharma Inc purchased 25,000 shares on Apr 5, 2016. The shares were purchased at $3.53 per share for a total value of ...
04/06/16 07:27 PMaTyr Pharma to Present at 15th Annual Needham & Company Healthcare Conference - PR Newswire (press release) - aTyr Pharma to Present at 15th Annual Needham & Company Healthcare ConferencePR Newswire (press release)SAN DIEGO, April 6, 2016 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the Company's ...and more »
About aTyr Pharma

aTyr Pharma logoaTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B. The Company is developing Resolaris, an intravenous protein therapeutic for the treatment of rare myopathies with an immune component (RMICs). The Company is investigating Resolaris in patients with LGMD2B. The Company is conducting approximately three open label trials in patients with early onset FSHD, in adult patients with FSHD or LGMD2B and a long-term extension study in adult patients with FSHD. The Company has not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Life Sciences Tools & Services
  • Exchange: NASDAQ
  • Symbol: LIFE
  • CUSIP: 53217V10
Key Metrics:
  • Previous Close: $2.78
  • 50 Day Moving Average: $3.07
  • 200 Day Moving Average: $4.88
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $65.85M
  • Current Quarter EPS Consensus Estimate: $-2.79 EPS
Additional Links:
aTyr Pharma (NASDAQ:LIFE) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha